Cardiovascular Diabetology

Journal Abbreviation: CARDIOVASC DIABETOL
ISSN: 1475-2840
Publisher: BioMed Central

Publications (16)

close-button

Types of publications

Journal article
Unpublished / Preprint

Publication year

From
To

Abstract

Is GFR decline induced by SGLT2 inhibitor of clinical importance? (2024) Günes-Altan M, Bosch A, Striepe K, Bramlage P, Schiffer M, Schmieder R, Kannenkeril D Journal article Different roles of protein biomarkers predicting eGFR trajectories in people with chronic kidney disease and diabetes mellitus: a nationwide retrospective cohort study (2023) Kammer M, Heinzel A, Hu K, Meiselbach H, Gregorich M, Busch M, Duffin KL, et al. Journal article Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk (2022) Boehm M, Schumacher H, Werner C, Teo KK, Lonn EM, Mahfoud F, Speer T, et al. Journal article Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers (2022) Geßner A, Gemeinhardt A, Bosch A, Kannenkeril D, Staerk C, Mayr A, Fromm M, et al. Journal article Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure (2021) Pietschner R, Kolwelter J, Bosch A, Striepe K, Jung S, Kannenkeril D, Ott C, et al. Journal article Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine (2021) Ott C, Jung S, Korn M, Kannenkeril D, Bosch A, Kolwelter J, Striepe K, et al. Journal article How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial (2019) Bosch A, Ott C, Jung S, Striepe K, Karg MV, Kannenkeril D, Dienemann T, Schmieder R Journal article Early vascular parameters in the micro- and macrocirculation in type 2 diabetes (2018) Kannenkeril D, Bosch A, Harazny J, Karg M, Jung S, Ott C, Schmieder R Journal article Individualised treatment targets in patients with type-2 diabetes and hypertension (2018) Schmieder R, Tschoepe D, Koch C, Ouarrak T, Gitt AK Journal article SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial (2018) Karg M, Bosch A, Kannenkeril D, Striepe K, Ott C, Schneider MP, Boemke-Zelch F, et al. Journal article